• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

上市后监测中控制物质的信号检测。

Signal detection in post-marketing surveillance for controlled substances.

机构信息

Department of Epidemiology, University of North Carolina Gillings School of Global Public Health, Chapel Hill, NC, USA.

出版信息

Drug Alcohol Depend. 2009 Dec 1;105 Suppl 1:S33-41. doi: 10.1016/j.drugalcdep.2009.05.019. Epub 2009 Jul 18.

DOI:10.1016/j.drugalcdep.2009.05.019
PMID:19616902
Abstract

Signal detection for pharmaceutical controlled substances presents unique challenges compared to other pharmacovigilance programs because risks are present in the patient and non-patient populations. Defining signals for controlled substances has been difficult because no specific empirical criteria have been established through regulatory actions or guidances. We start with a review of data sources available for decision making to regulators and industry. In this paper we present a framework for processing signals received during post-marketing surveillance: signal identification, verification and assessment, followed by intervention and evaluation. Signal identification involves processing qualitative and quantitative information in order to generate hypotheses describing concerns with controlled substances. Integration of heterogeneous data sources makes this process difficult and we describe multiple approaches utilized in practice today. Signal verification currently relies heavily on telephone interviews with stakeholders in local communities. Once information on a potential signal has been gathered signal assessment is a higher order process conducted with an eye towards broader societal expectations and the ability to intervene or further study the problem. Intervention and evaluation complete the cycle of signal assessment and triage. This paper is intended as a primer of the current practice of signal assessment in the post-marketing surveillance for controlled substances.

摘要

与其他药物警戒计划相比,药物管制物质的信号检测提出了独特的挑战,因为患者和非患者人群都存在风险。由于没有通过监管行动或指南确立特定的经验标准,因此管制物质的信号定义一直存在困难。我们首先回顾了决策者和行业可用的决策数据来源。在本文中,我们提出了一个在上市后监测期间处理接收到的信号的框架:信号识别、验证和评估,然后是干预和评估。信号识别涉及处理定性和定量信息,以便生成描述对管制物质关注的假设。异构数据源的集成使这一过程变得困难,我们描述了当今实践中使用的多种方法。目前,信号验证主要依赖于与当地社区利益相关者的电话访谈。一旦收集到关于潜在信号的信息,信号评估就是一个更高层次的过程,着眼于更广泛的社会期望和干预或进一步研究问题的能力。干预和评估完成了信号评估和分类的循环。本文旨在介绍管制物质上市后监测中信号评估的当前实践。

相似文献

1
Signal detection in post-marketing surveillance for controlled substances.上市后监测中控制物质的信号检测。
Drug Alcohol Depend. 2009 Dec 1;105 Suppl 1:S33-41. doi: 10.1016/j.drugalcdep.2009.05.019. Epub 2009 Jul 18.
2
Monitoring risk: post marketing surveillance and signal detection.监测风险:上市后监测和信号检测。
Drug Alcohol Depend. 2009 Dec 1;105 Suppl 1:S26-32. doi: 10.1016/j.drugalcdep.2009.08.011. Epub 2009 Sep 12.
3
Risk management and post-marketing surveillance of CNS drugs.中枢神经系统药物的风险管理和上市后监测。
Drug Alcohol Depend. 2009 Dec 1;105 Suppl 1:S56-64. doi: 10.1016/j.drugalcdep.2009.08.004. Epub 2009 Sep 19.
4
National addictions vigilance intervention and prevention program (NAVIPPRO): a real-time, product-specific, public health surveillance system for monitoring prescription drug abuse.国家成瘾监测、干预与预防项目(NAVIPPRO):一个用于监测处方药滥用情况的实时、针对特定产品的公共卫生监测系统。
Pharmacoepidemiol Drug Saf. 2008 Dec;17(12):1142-54. doi: 10.1002/pds.1659.
5
[Procedures and methods of benefit assessments for medicines in Germany].[德国药品效益评估的程序和方法]
Dtsch Med Wochenschr. 2008 Dec;133 Suppl 7:S225-46. doi: 10.1055/s-0028-1100954. Epub 2008 Nov 25.
6
An evaluation of computer-aided disproportionality analysis for post-marketing signal detection.上市后信号检测的计算机辅助不成比例性分析评估。
Clin Pharmacol Ther. 2007 Aug;82(2):173-80. doi: 10.1038/sj.clpt.6100233. Epub 2007 May 16.
7
Automated support for pharmacovigilance: a proposed system.药物警戒的自动化支持:一个提议的系统。
Pharmacoepidemiol Drug Saf. 2002 Mar;11(2):121-5. doi: 10.1002/pds.684.
8
Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.转基因植物及其衍生食品和饲料的安全性与营养评估:动物饲养试验的作用
Food Chem Toxicol. 2008 Mar;46 Suppl 1:S2-70. doi: 10.1016/j.fct.2008.02.008. Epub 2008 Feb 13.
9
Estimating post-marketing exposure to pharmaceutical products using ex-factory distribution data.利用出厂销售数据估算药品上市后的暴露情况。
Pharmacoepidemiol Drug Saf. 2006 Oct;15(10):749-53. doi: 10.1002/pds.1264.
10
Pharmacovigilance in Europe and North America: divergent approaches.欧洲和北美的药物警戒:不同的方法。
Soc Sci Med. 2012 Jul;75(1):165-70. doi: 10.1016/j.socscimed.2011.11.046. Epub 2012 Apr 3.

引用本文的文献

1
Invited Commentary: Drug Checking for Novel Insights Into the Unregulated Drug Supply.邀请评论:药物检测对非管制药物供应的新见解。
Am J Epidemiol. 2022 Jan 24;191(2):248-252. doi: 10.1093/aje/kwab233.
2
The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act.根据《管制物质法案》的 8 个因素,评估医用迷幻蘑菇的滥用潜力。
Neuropharmacology. 2018 Nov;142:143-166. doi: 10.1016/j.neuropharm.2018.05.012. Epub 2018 Jun 5.
3
Using Social Listening Data to Monitor Misuse and Nonmedical Use of Bupropion: A Content Analysis.
利用社交倾听数据监测安非他酮的滥用和非医疗用途:一项内容分析。
JMIR Public Health Surveill. 2017 Feb 1;3(1):e6. doi: 10.2196/publichealth.6174.
4
Agonist Medications for the Treatment of Cocaine Use Disorder.用于治疗可卡因使用障碍的激动剂药物。
Neuropsychopharmacology. 2015 Jul;40(8):1815-25. doi: 10.1038/npp.2014.322. Epub 2014 Dec 11.
5
Multiple Determinants of Specific Modes of Prescription Opioid Diversion.处方阿片类药物特定转移模式的多种决定因素。
J Drug Issues. 2011 Spring;41(2):283-304. doi: 10.1177/002204261104100207.
6
Conference on abuse liability and appeal of tobacco products: conclusions and recommendations.滥用和吸引力评估会议烟草产品:结论和建议。
Drug Alcohol Depend. 2011 Jul 1;116(1-3):1-7. doi: 10.1016/j.drugalcdep.2010.12.009. Epub 2011 Mar 3.
7
Postmarketing surveillance for "modified-risk" tobacco products.“改良风险”烟草产品的上市后监测。
Nicotine Tob Res. 2012 Jan;14(1):29-42. doi: 10.1093/ntr/ntq243. Epub 2011 Jan 20.
8
Abuse liability assessment of tobacco products including potential reduced exposure products.烟草制品(包括潜在减害产品)的滥用倾向评估。
Cancer Epidemiol Biomarkers Prev. 2009 Dec;18(12):3241-62. doi: 10.1158/1055-9965.EPI-09-0948.
9
Risk management and post-marketing surveillance for the abuse of medications acting on the central nervous system: expert panel report.作用于中枢神经系统药物的滥用的风险管理和上市后监测:专家小组报告。
Drug Alcohol Depend. 2009 Dec 1;105 Suppl 1(Suppl 1):S65-71. doi: 10.1016/j.drugalcdep.2009.08.006. Epub 2009 Sep 23.
10
Principles of laboratory assessment of drug abuse liability and implications for clinical development.药物滥用倾向的实验室评估原则及其对临床开发的影响。
Drug Alcohol Depend. 2009 Dec 1;105 Suppl 1:S14-25. doi: 10.1016/j.drugalcdep.2009.04.003. Epub 2009 May 14.